Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514862 | 0.93 | HRH3 (0.40) | JAK2JAK3PTK2HRH3KCNH2 | |
| SCHEMBL3514756 | 0.80 | PIK3CA (0.57) | HRH3TNFKCNH2PDK2 | |
| SCHEMBL4060345 | 0.78 | KCNH2 (0.50) | JAK2JAK3PTK2TNFKCNH2 | |
| SCHEMBL4055601 | 0.76 | JAK2 (0.47) | JAK2JAK3PTK2TNFKCNH2 | |
| SCHEMBL13589470 | 0.74 | POLB (0.52) | HRH3KCNH2KMT2APDK2BRD4 | |
| SCHEMBL3514500 | 0.73 | HRH3 (0.46) | JAK2HRH3KCNH2RCE1PDK2 | |
| SCHEMBL4054695 | 0.71 | KCNH2 (0.44) | JAK2JAK3PTK2TNFKCNH2 | |
| SCHEMBL4054844 | 0.69 | PIK3CA (0.51) | TNFKCNH2KMT2ABRD4FYN | |
| SCHEMBL4056586 | 0.69 | PIK3CA (0.57) | KCNH2KMT2ABRD4FYN | |
| SCHEMBL4052345 | 0.68 | PIK3CA (0.52) | TNFKCNH2KMT2ABRD4FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | JAK2 98/4885JAK3 241/4885PTK2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.